PRT2527 + Zanubrutinib + Venetoclax
Phase 1CompletedDevelopment Stage
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Sep 12, 2023 → Jan 21, 2026
About PRT2527 + Zanubrutinib + Venetoclax
PRT2527 + Zanubrutinib + Venetoclax is a phase 1 stage product being developed by Prelude Therapeutics for Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). The current trial status is completed. This product is registered under clinical trial identifier NCT05665530. Target conditions include Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05665530 | Phase 1 | Completed |
Competing Products
11 competing products in Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy | Johnson & Johnson | Phase 2 | 52 |
| Loncastuximab Tesirine and Epcoritamab | AbbVie | Phase 2 | 52 |
| Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib | AstraZeneca | Phase 2 | 52 |
| Midostaurin | Novartis | Phase 2 | 52 |
| Imatinib | Novartis | Phase 2 | 52 |
| Bendamustine and subcutaneous rituximab | Roche | Phase 2 | 52 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 1/2 | 40 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 2 | 51 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| cemiplimab + odronextamab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |